Decision letter for "Lower Risk of Cardiovascular Events in Patients with Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-world: Results from the SCORE - Clinical ASCVD study"
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
Diabetes Treatment and Management
Diabetes
Cardiovascular Risks
and Lipoproteins
Heart Failure Treatment and Management
Publication details
- Journal / source
- Publons reviews and discussion
- Publication date
- 11 March 2026
- Language
- EN